Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 7/20 | 0.42 |
| ▸ | PPARG | P37231 | 5/20 | 0.42 |
| ▸ | RARA | P10276 | 3/20 | 0.41 |
| ▸ | RXRB | P28702 | 3/20 | 0.41 |
| ▸ | RXRG | P48443 | 3/20 | 0.41 |
| ▸ | RARB | P10826 | 2/20 | 0.41 |
| ▸ | RARG | P13631 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4860880 | 0.74 | RXRA (0.47) | RXRAPPARGRARARXRBRXRG | |
| SCHEMBL14203397 | 0.72 | RXRA (0.49) | RXRAPPARGRARARXRBRXRG | |
| SCHEMBL6706020 | 0.70 | RXRA (0.61) | RXRAPPARGRARARXRBRXRG | |
| SCHEMBL6706019 | 0.70 | RXRA (0.61) | RXRAPPARGRARARXRBRXRG | |
| SCHEMBL6705749 | 0.68 | RXRA (0.67) | RXRAPPARGRARARXRBRXRG | |
| SCHEMBL6705747 | 0.68 | RXRA (0.67) | RXRAPPARGRARARXRBRXRG | |
| SCHEMBL26259695 | 0.67 | GABRA1 (0.32) | — | |
| SCHEMBL6833506 | 0.66 | RXRA (0.61) | RXRAPPARGRARARXRBRXRG | |
| SCHEMBL6707051 | 0.65 | RXRA (0.70) | RXRAPPARGRARARXRBRXRG | |
| SCHEMBL6707048 | 0.65 | RXRA (0.70) | RXRAPPARGRARARXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040248919-A1 | Fluorinated trienes and their use as rxr modulators | ELI LILLY AND COMPANY | 2004-12-09 | — | — | US | disclosed |
| EP-1368296-A1 | FLUORINATED TRIENES AND THEIR USE AS RXR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-12-10 | — | — | EP | disclosed |
| WO-2002072528-A1 | FLUORINATED TRIENES AND THEIR USE AS RXR MODULATORS | ELI LILLY AND COMPANY (US) | 2002-09-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248919-A1 | Fluorinated trienes and their use as rxr modulators | RXRA, THRA, RXRB | RXRA 1/4885PPARG 20/4885RARA 29/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.